Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lifecore Biomedical, Inc. \De\ (LFCR) EBIT Margin (2016 - 2025)

Historic EBIT Margin for Lifecore Biomedical, Inc. \De\ (LFCR) over the last 17 years, with Q2 2025 value amounting to 14.62%.

  • Lifecore Biomedical, Inc. \De\'s EBIT Margin rose 89400.0% to 14.62% in Q2 2025 from the same period last year, while for May 2025 it was 13.38%, marking a year-over-year decrease of 64900.0%. This contributed to the annual value of 13.38% for FY2025, which is 64900.0% down from last year.
  • As of Q2 2025, Lifecore Biomedical, Inc. \De\'s EBIT Margin stood at 14.62%, which was up 89400.0% from 25.68% recorded in Q1 2025.
  • Lifecore Biomedical, Inc. \De\'s 5-year EBIT Margin high stood at 14.62% for Q2 2025, and its period low was 46.89% during Q3 2024.
  • Its 5-year average for EBIT Margin is 12.51%, with a median of 11.56% in 2022.
  • As far as peak fluctuations go, Lifecore Biomedical, Inc. \De\'s EBIT Margin skyrocketed by 278400bps in 2021, and later plummeted by -388900bps in 2022.
  • Quarter analysis of 5 years shows Lifecore Biomedical, Inc. \De\'s EBIT Margin stood at 14.41% in 2021, then plummeted by -270bps to 24.48% in 2022, then soared by 80bps to 4.92% in 2023, then dropped by -22bps to 6.02% in 2024, then soared by 343bps to 14.62% in 2025.
  • Its EBIT Margin stands at 14.62% for Q2 2025, versus 25.68% for Q1 2025 and 6.02% for Q4 2024.